Vaxcell-Bio Therapeutics
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Vaxcell-Bio Therapeutics develops cell-based therapies, treatments that use a patient's own immune cells to fight disease, with a focus on cancer immunotherapy.
Its products are aimed at clinical and hospital settings where patients require advanced biological treatments. The company is listed on KOSDAQ, South Korea's technology and small-cap stock exchange, and is currently in a development-stage phase, generating revenue while continuing to invest heavily in research.
Summary is AI-generated and may contain errors · figures from DART filings
Vaxcell-Bio Therapeutics in five facts
What does Vaxcell-Bio Therapeutics do?
Vaxcell-Bio Therapeutics develops cell-based therapies, treatments that use a patient's own immune cells to fight disease, with a focus on cancer immunotherapy.
Where is Vaxcell-Bio Therapeutics listed and in which sector?
Vaxcell-Bio Therapeutics (Korean name: 박셀바이오) trades under KRX code 323990 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Biotechnology.
How large is Vaxcell-Bio Therapeutics?
Its market capitalisation was US$74.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Vaxcell-Bio Therapeutics's latest annual revenue and operating profit?
For fiscal year 2025, Vaxcell-Bio Therapeutics reported revenue of US$5.3M, an operating loss of US$11.7M and a net loss of US$10.1M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 271.6% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.